CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.09) by 136.56 percent. This is a 195.65 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $663.000 thousand which missed the analyst consensus estimate of $7.900 million by 91.61 percent. This is a 98.26 percent decrease over sales of $38.093 million the same period last year.